Table 2.

Estimates for the change from baseline in secondary end‐points, by population (FAS)

	UUI population		MUI population
	Placebo (n = 204)	Mirabegron 50 mg (n = 214)	Placebo (n = 122)	Mirabegron 50 mg (n = 139)
Urgency episodes/24 h
Median value at baseline (Q1–Q3)	4.33 (2.67–6.67)	4.33 (2.67–6.33)	3.67 (2.67–5.67)	4.33 (2.67–6.33)
Estimate of the median change (95% two‐sided CI)†	−1.83 (−2.17, −1.5)	−2.50 (−2.83, −2.17)	−1.67 (−2.17, −1.17)	−2.17 (−2.50, −1.83)
Difference in median change versus placebo (95% two‐sided CI)†		−0.67 (−1.00, −0.33)		−0.50 (−1.00, −0.00)
Two‐sided P‐value‡		0.002		0.266
Incontinence episodes/24 h
Median value at baseline (Q1–Q3)	1.33 (0.67–2.33)	1.67 (1.00–2.67)	1.67 (0.67–2.33)	1.33 (0.67–3.00)
Estimate of the median change (95% two‐sided CI)†	−0.67 (−0.83, −0.50)	−1.00 (−1.17, −1.00)	−0.67 (−0.83, −0.50)	−1.17 (−1.33, −1.00)
Difference in median change versus placebo (95% two‐sided CI)†		−0.33 (−0.67, 0.00)		−0.50 (−0.67, −0.33)
Two‐sided P‐value‡		0.002		<0.001
Mean voided volume/micturition
Median value at baseline (Q1–Q3)	143.261 (117.742–176.875)	141.584 (114.211–180.789)	140.769 (117.000–179.531)	148.267 (120.962–185.000)
Estimate of the median change (95% two‐sided CI)†	6.303 (2.244–10.439)	25.619 (21.144–30.070)	14.578 (8.301–20.685)	24.839 (19.476–30.837)
Difference in median change versus placebo (95% two‐sided CI)†		19.203 (13.121–25.285)		10.973 (3.363–18.583)
Two‐sided P‐value‡		<0.001		0.005
Nocturia episodes/night
Median value at baseline (Q1–Q3)	1.50 (1.00–2.00)	1.50 (1.00–2.50)	1.50 (1.00–2.50)	1.50 (1.00–2.00)
Estimate of the median change (95% two‐sided CI)†	−0.25 (−0.50, −0.25)	−0.50 (−0.50, −0.25)	−0.25 (−0.50, 0.00)	−0.50 (−0.50, −0.25)
Difference in median change versus placebo (95% two‐sided CI)†		0.00 (0.00, 0.00)		−0.25 (−0.50, 0.00)
Two‐sided P‐value‡		0.588		0.030

^†The Hodges–Lehmann method was used to obtain an estimate in the median (and 95% CI) change.

^‡Ranked ancova (vs placebo).